Hope for dry macular degeneration patients as treatment costs surge

Hope for dry macular degeneration patients as treatment costs surge

Dry macular degeneration is the leading cause of blindness in Australian adults and while there is no cure, new treatments are showing promising results. But they’re costly and some are about to get even more expensive.

Avid bridge player Rene Sharp couldn’t believe her eyes when her game slipped out of sight.

WATCH THE VIDEO ABOVE: New hope for macular degeneration patients

Know the news with the 7NEWS app: Download today Arrow

“I couldn’t tell the difference between the spades and the clubs,” she said.

Diagnosed with dry age-related macular degeneration, a gradual deterioration of the macula leading to vision loss, Sharp faced an uncertain future.

There is no cure but ophthalmologists say new treatments are offering hope.

Eye surgeon Dr Shanel Sharma says two treatments are showing promise – dry macular injections and Macumera.

Rene Sharp suffers from dry macular degeneration. Credit: 7NEWSMacumera is a new treatment. Credit: 7NEWS

Macumera is a non-invasive treatment that stimulates the retina using low-level microcurrent pulses delivered through closed eyelids, stimulating cells to produce more energy and improve function.

“In fact, all the patients have improved by at least one line,” Sharma said.

For Sharp, not only is she back playing bridge, she was able to regain her driver’s licence.

“I had such doubts. I thought I would never pass, but I did,” she said.

But researchers are still casting a cautious eye over the technology.

Researchers are still casting doubts over the technology. Credit: 7NEWS

Researcher Professor Robyn Guymer warned: “Just because it’s available does not mean it’s gone through the rigorous testing like a drug, and it hasn’t at the moment.”

The other treatment, the injections, have been found to slow the loss of vision, but they could soon be out of reach for many.

The producer has withdrawn its application for the pharmaceutical benefit scheme, so they’ll soon cost patients around $18,000 a year.

Biogen said the decision to withdraw was based on the proposed reimbursement criteria under consideration in Australia.

“There’s another one called Izervay, and they are similarly looking to see whether they can get a broader indication for use on the PBS,” Guymer said.

Man, pregnant woman found dead in outback home identified

1 min read

Athlete denies ‘sinister’ Alan Jones spin: ‘Absolutely not’

3 min read

Leave a Reply

Your email address will not be published. Required fields are marked *